Abstract
Objective To investigate the predictive value of serum neopterin for multiple organ dysfunction syndrome (MODS) in severe burn patients. Methods Seventy-six severe burn patients with burns covering a total body surface area (TBSA) above 70% were included in this study. Of the 76 patients, 29 cases developed MODS (MODS group) and the remaining 47 subjects did not (non-MODS group). From the MODS group, 12 patients died (Death group) and 17 patients survived (Survive group). The serum level of neopterin in the MODS and non-MODS groups were examined by radioimmunoassay on following 1, 3 , 7 , 14 , 21 and 28 post-burn days (PBDs). A receiver operating characteristic (ROC) curve was used to analyse the predictive value of serum neopterin for MODS and death. Results The serum neopterin level in the MODS group was significantly higher than that of non-MODS group between 3~28 PBDs (p<0.001). However, the serum neopterin levels between the MODS and non-MODS groups following 1 PBD were not statistically significant (p>0.05). The best diagnostic performance of serum neopterin for MODS occurred 14 PBDs with the prediction sensitivity and specificity of 75.86% (56.46%~89.70%) and 85.11% (71.69%~93.80%) respectively. However, serum neopterin levels had no clinical value in predicting the death of MODS patients. The area under the ROC curve (AUC) was 0.72 (0.58~0.85), 0.81 (0.71~0.92) and 0.83 (0.72~0.94) for serum neopterin as biomarker in the prediction of MODS after 3, 7 and 14 PBDs, respectively. The AUCs were 0.50 (0.27~0.73), 0.53 (0.30~0.76) and 0.56 (0.33~0.79) for serum neopterin as biomarker in prediction of death for MODS patients after 3, 7 and 14 PBDs, respectively. Conclusion The persistent and significant increase of serum neopterin level is closely related to the development of MODS in patients with severe burns. Serum neopterin is therefore a promising serological marker for MODS early diagnosis, but has little efficacy in the prediction of the likelihood of death in severe burn patients with MODS.
References
1. Ramirez M. Multiple organ dysfunction syndrome. Curr Probl Pediatr Adolesc Health Care 2013;43:273-7.10.1016/j.cppeds.2013.10.003Search in Google Scholar
2. Chai JK, Sheng ZY. [The present strategy and ponderation on prevention and treatment of burn sepsis and multiple organ dysfunction syndrome (MODS)]. Zhonghua shao shang za zhi = Zhonghua shaoshang zazhi = Chinese journal of burns 2008;24:378-80.Search in Google Scholar PubMed
3. Osuka A, Kusuki H, Matsuura H, Shimizu K, Ogura H, Ueyama M. Acute intestinal damage following severe burn correlates with the development of multiple organ dysfunction syndrome: A prospective cohort study. Burns 2017;43:824-829.10.1016/j.burns.2016.10.015Search in Google Scholar PubMed
4. Nguyen LN, Nguyen TG. Characteristics and outcomes of multiple organ dysfunction syndrome among severe-burn patients. Burns 2009;35:937-41.10.1016/j.burns.2009.04.015Search in Google Scholar PubMed
5. Chai JK, Sheng ZY. [The present strategy and ponderation on prevention and treatment of burn sepsis and multiple organ dysfunction syndrome (MODS)]. Zhonghua shao shang za zhi = Zhonghua shaoshang zazhi = Chinese journal of burns 2008;24:378-80.Search in Google Scholar PubMed
6. Rawlingson A. Nitric oxide, inflammation and acute burn injury. Burns 2003;29:631-40.10.1016/S0305-4179(03)00079-2Search in Google Scholar
7. Gieseg SP, 0000-0002-3862-1385 AO, Baxter-Parker G, Lindsay A. Neopterin, Inflammation, and Oxidative Stress: What Could We Be Missing. Antioxidants (Basel, Switzerland) 2018;7.10.3390/antiox7070080Search in Google Scholar PubMed PubMed Central
8. Uchiyama Y. [Neopterin]. Nihon rinsho. Japanese journal of clinical medicine 2005;63 Suppl 8:748-52.Search in Google Scholar
9. Melichar B, Spisarova M, Bartouskova M, Krcmova LK, Javorska L, Studentova H. Neopterin as a biomarker of immune response in cancer patients. Annals of translational medicine 2017;5:280.10.21037/atm.2017.06.29Search in Google Scholar PubMed PubMed Central
10. Kozlowska-Murawska J, Obuchowicz AK. [Clinical usefulness of neopterin]. Wiadomosci lekarskie (Warsaw, Poland : 1960) 2008;61:269-72.Search in Google Scholar
11. Ghanem AM, Sen S, Philp B, Dziewulski P, Shelley OP. Body Mass Index (BMI) and mortality in patients with severe burns: is there a “tilt point” at which obesity influences outcome. Burns 2011;37:208-14.10.1016/j.burns.2010.08.010Search in Google Scholar PubMed
12. Barrow RE, Herndon DN. Incidence of mortality in boys and girls after severe thermal burns. Surgery, gynecology & obstetrics 1990;170:295-8.Search in Google Scholar
13. Yao YM, Redl H, Bahrami S, Schlag G. The inflammatory basis of trauma/shock-associated multiple organ failure. Inflammation research : official journal of the European Histamine Research Society ... [et al.] 1998;47:201-10.10.1007/s000110050318Search in Google Scholar
14. Mildvan D, Spritzler J, Grossberg SE, Fahey JL, Johnston DM, Schock BR, Kagan J. Serum neopterin, an immune activation marker, independently predicts disease progression in advanced HIV-1 infection. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2005;40:853-8.10.1086/427877Search in Google Scholar PubMed
15. Wirleitner B, Schroecksnadel K, Winkler C, Fuchs D. Neopterin in HIV-1 infection. Mol Immunol 2005;42:183-94.10.1016/j.molimm.2004.06.017Search in Google Scholar PubMed
16. Demirturk N, Demirdal T, Aktepe OC, Aykin N, Orhan S, Cevik F. Serum neopterin levels in patients with HBV infection at various stages. Hepatogastroenterology 2007;54:903-5.Search in Google Scholar
17. Kaleli I, Demir M, Cevahir N, Yilmaz M, Demir S. Serum neopterin levels in patients with replicative and nonreplicative HBV carriers. BMC Infect Dis 2006;6:157.10.1186/1471-2334-6-157Search in Google Scholar PubMed PubMed Central
18. El-Lebedy D, Hussein J, Ashmawy I, Mohammed AM. Serum level of neopterin is not a marker of disease activity in treated rheumatoid arthritis patients. Clin Rheumatol 2017;36:1975-1979.10.1007/s10067-016-3433-4Search in Google Scholar
19. Arshadi D, Nikbin B, Shakiba Y, Kiani A, Jamshidi AR, Boroushaki MT. Plasma level of neopterin as a marker of disease activity in treated rheumatoid arthritis patients: association with gender, disease activity and anti-CCP antibody. Int Immunopharmacol 2013;17:763-7.10.1016/j.intimp.2013.08.022Search in Google Scholar
20. Mahmoud RA, El-Gendi HI, Ahmed HH. Serum neopterin, tumor necrosis factor-alpha and soluble tumor necrosis factor receptor II (p75) levels and disease activity in Egyptian female patients with systemic lupus erythematosus. Clin Biochem 2005;38:134-41.10.1016/j.clinbiochem.2004.11.002Search in Google Scholar
21. Leohirun L, Thuvasethakul P, Sumethkul V, Pholcharoen T, Boonpucknavig V. Urinary neopterin in patients with systemic lupus erythematosus. Clin Chem 1991;37:47-50.10.1093/clinchem/37.1.47Search in Google Scholar
22. Balogh D, Lammer H, Kornberger E, Stuffer M, Schonitzer D. Neopterin plasma levels in burn patients. Burns 1992;18:185-8.10.1016/0305-4179(92)90068-6Search in Google Scholar
23. Yao Y, Sheng Z, Chen J. [The predictive value of serum neopterin for multiple organ dysfunction syndrome in extensively burned patients]. Zhonghua shao shang za zhi = Zhonghua shaoshang zazhi = Chinese journal of burns 2001;17:142-5.Search in Google Scholar
© 2019 Wei Xiong, et al., published by Sciendo
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.
